Empowered Funds LLC Has $643,000 Stake in Masimo Co. (NASDAQ:MASI)

Empowered Funds LLC grew its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 85.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,891 shares of the medical equipment provider's stock after acquiring an additional 1,796 shares during the quarter. Empowered Funds LLC's holdings in Masimo were worth $643,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. UMB Bank n.a. increased its position in Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after acquiring an additional 123 shares during the period. Trust Co. of Vermont bought a new position in Masimo in the 4th quarter valued at about $33,000. Blue Trust Inc. increased its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares during the period. GAMMA Investing LLC increased its holdings in Masimo by 136.5% in the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider's stock valued at $77,000 after buying an additional 269 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in Masimo in the 3rd quarter valued at about $118,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MASI has been the topic of several recent analyst reports. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, December 18th. Stifel Nicolaus reissued a "buy" rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Raymond James raised their target price on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $191.40.

Masimo Trading Down 4.1 %

NASDAQ:MASI traded down $7.25 during mid-day trading on Friday, hitting $169.96. 603,597 shares of the company's stock were exchanged, compared to its average volume of 474,198. The company has a 50 day simple moving average of $172.90 and a 200-day simple moving average of $151.29. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $184.51. The firm has a market capitalization of $9.10 billion, a P/E ratio of 117.21 and a beta of 1.02.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.